They updated the agreement a while back (among other things ITMN didn't get the upfront money on 2nd generation but I believe Roche was responsible for picking up the cost on all preclinical and I think Phase 1 work too). I am not sure if they updated the exclusivity then or not but in the original agreement Roche could not license or develop another PI while 191 was in development or until some date much further in the future (I don't recall the date but it was in the 2011-2013 range). NOw I am not sure if Roche can just flat out drop it because they think its got a safety signal or the market dynamics have changed. ITMN claimed equal say on jt comittee's with Roche taking the lead if I recall correctly.
Market Data 
Markets 
AI
